Sandoz Group AG (SDZ) Fair Value & Analysis
Healthcare · CH · Market cap CHF 28.0B · ISIN CH1243598427
What is Sandoz Group AG really worth?
A solid business, but trading 74% above our fair value of CHF 39.21.
Strengths
Risks
For context
Fair value as of: Aug 27, 2026
From 26 valuation models · updated 9 days ago
Fair value updated Aug 27, 2026, revised from CHF 48.68 to CHF 39.21 (−19.5%) since Aug 13, 2026. Share price +0.3% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (CHF 49.01). The favourable scenario is already priced in.
- Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (CHF 21.72 to CHF 49.01) leaves room in how you read the outcome.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 27, 2026.
How to read this chart
35‑month range CHF 22.61 – CHF 74.90 · fair‑value band CHF 21.72 – CHF 49.01 · the CHF 68.36 price screens above the CHF 39.21 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 27, 2026.
Analysis
Sandoz Group AG (SDZ) currently trades at CHF 68.36, while our model-based Fair Value estimate is CHF 39.21, implying the stock looks roughly 74.3% overvalued today. The Quality Score stands at 56/100 (solid quality), in the Healthcare sector. Bull case: the Multiples group reads highest at a median of CHF 46.83 per share, and 2 of the 26 models we run sit above the CHF 68.36 price. Bear case: the Dividend Discount group reads lowest at CHF 11.72, and 24 of the 26 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Sandoz Group AG generated revenue of CHF 11.2B at a net margin of 8.2%. Revenue grew 10.7% year over year. It earns a return on equity of 10.4%. Net debt stands at CHF 3.9B. Fundamentals as of Aug 27, 2026
Our scenario range runs from CHF 21.72 (bear case) to CHF 49.01 (bull case); at CHF 68.36, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 5% below its 52-week high and 67% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −49% fair-value upside, at −43%, SDZ screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly CHF 0.4608 per share, which is 1.2 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: Multiples (CHF 46.83) versus Dividend Discount (CHF 11.72). Highest evidence: FCF DCF (76).
Notify me when SDZ reaches fair value
Put SDZ on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 27, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 72
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and …
Full company description
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sandoz Group AG reported revenue of $11.6B in FY2025 versus $8.8B in FY2021, a compound +7.1%/yr. Reported net income was $957M in FY2025, compounding +3.7%/yr from FY2021.
SDZ screens 74% overvalued. Compare with Merck KGaA →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Sandoz targets industry patent void with $322m Henlius deal
- Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform
- Sandoz Group AG (SDZNY) (H1 2026) Earnings Call Highlights: Biosimilar Growth Drives 5% Sales ...
- Sandoz Group (SWX:SDZ) Settles US Drug Pricing Cases And Wins Brazil Semaglutide Approval
Peer Group
Drug Manufacturers - Specialty & Generic · 608 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 27, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | −49% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $36.05 | $15.33 | −57% |
| Zoetis Inc ZTS | $77.10 | $104.88 | +36% |
| Hansoh Pharmaceutical Group 3692 | HK$35.12 | HK$16.18 | −54% |
| Divi's Laboratories Limited DIVISLAB | ₹8,525 | ₹1,228 | −86% |
Compare Sandoz Group AG with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Sandoz Group AG (SDZ) overvalued or undervalued?
What is the fair value of SDZ?
What is the quality score of SDZ?
What is the revenue of Sandoz Group AG (SDZ)?
What is the net profit margin of SDZ?
Does Sandoz Group AG pay a dividend?
Watch Sandoz Group AG in the live analysis
One click puts Sandoz Group AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.